JPM2026

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Digital

pharmaphorum podcast Episode 242, Yann Gaston-Mathe, Iktos

JPM2026: Broadening AI drug discovery to include the lab, wi...

Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.

R&D

Interview at JPM26 with Adrian Woolfson and Kaihang Wang from Genyro

DNA as a programmable language, with Adrian Woolfson and Kai...

A new technology just announced this weekend in a paper in Nature could have a radical impact on how gene assembly is carried out.

Digital

Is DTx finally reaching drug-like efficacy? A Q&A with David...

Click Therapeutics CEO David Benshoof Klein shares thoughts on what's been holding DTx back and why this could be the moment for a breakout.

JPM2026

Editor's Picks